Serum Uric Acid level as a Part of the Metabolic Syndrome Impairs the Coronary Collateral Formation

Abstract

Get full access to this article

View all access options for this article.

References

Duran

Ornek

Murat

. High levels of serum uric acid impair development of coronary collaterals in patients with acute coronary syndrome. Angiology. 2011. doi: 10.1177/000331971142243.

Chilian

Mass

Williams

Layne

Smith

Scheel

. Microvascular occlusions promote coronary collateral growth. Am J Physiol. 1990;258:H1103–H11011.

Basaga

. Biochemical aspects of free radicals. Biochem Cell Biol. 1990;68 ( 7-8 ):989–998.

Ruggiero

Cherubini

Ble

. Uric acid and inflammatory markers. Eur Heart J. 2006;27 ( 10 ):1174–1181.

Liese

Hense

Löwel

Döring

Tietze

Keil

. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology. 1999;10 (4):391–397.

Brand

McGee

Kannel

Stokes

J III

Castelli

. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol. 1985;121 (1):11–18.

Wannamethee

Shaper

Whincup

. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78 (2):147–153.

Conen

Wietlisbach

Bovet

. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:9.

Puig

Martínez

. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008;20 (2):187–191.

10.

Yilmaz

Caldir

Guray

. Relation of coronary collateral vessel development in patients with a totally occluded right coronary artery to the metabolic syndrome. Am J Cardiol. 2006;97 (5):636–639.

11.

Sasmaz

Yilmaz

. Coronary collaterals in obese patients: impact ofmetabolic syndrome. Angiology. 2009;60(2):164–168.

12.

Mouquet

Cuilleret

Susen

. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J. 2009;30(7):840–849.